California-based Zeto is using AI to enhance bedside EEG monitoring with automated detection and notifications for status epilepticus, a life-threatening, prolonged seizure condition requiring immediate intervention.

This uses FDA-cleared EEG analysis software from Encevis (www.encevis.com), developed by the Austrian Institute of Technology.

Up to a third of neurological critical care and emergency department patients are at risk for seizures, which can lead to permanent brain injury and increased mortality risk. Access to timely EEG interpretation remains an unmet need, particularly in emergency and critical care settings, where rapid and reliable medical intervention is essential.

“Our product development has been guided by neurologists, critical and emergency care physicians who sought rapid, clinical-grade EEG with full-head coverage and video to not miss clinically relevant events,” said Aswin Gunasekar, CEO of Zeto. “They emphasised the need for accurate bedside seizure detection that enables real-time review and validation by neurologists, ensuring patients receive timely and appropriate treatment. We introduced the Zeto One, a best-in-class, full 10-20 EEG system offering rapid setup, video and remote reading services, being fast embraced by US hospitals. With the addition of AI-powered seizure detection, we now offer a comprehensive, all-in-one option that significantly enhances neurocritical assessment.”

Encevis uses an AI model to detect seizures, seizure burden and electrographic status epilepticus. Trained on a diverse dataset of over 21,400 hours of EEG recordings from more than 800 patients, the model was further validated using an independent dataset from 81 patients. Expert reviewers from US and European institutions meticulously labelled the data, ensuring highly accurate and clinically meaningful insights.

“We are delighted to continue our successful partnership with Zeto,” said Tilmann Kluge, head of medical signal analysis at the Austrian Institute of Technology (www.ait.ac.at). “Our algorithms allow physicians to detect seizure burden and electrographic status epilepticus early and with high sensitivity without the need for continuous expert monitoring of the EEG. Our EEG analysis software has been utilised by leading hospitals for over a decade, with capabilities such as artefact reduction, spike and seizure detection with high sensitivity and specificity.”

Zeto’s full 10-20 EEG platform now features AI-powered seizure burden detection with EEG analysis tools providing comprehensive clinical value for ICU monitoring as required by ACNS, the American Clinical Neurophysiology Society (www.acns.org). Supported by nationwide neurologist reading services, hospitals can expand EEG access without additional infrastructure.

Through its wearable devices, Zeto (zeto-inc.com) makes brain monitoring accessible in diverse clinical settings, including the ICU, ED, hospitals, offices and at home. Backed by a cloud-based platform, it delivers nationwide monitoring and interpretation services by neurologists, along with AI-driven notifications for conditions such as seizures and epilepsy. Looking ahead, Zeto plans to expand its capabilities to detect and manage conditions such as depression, stroke and traumatic brain injury.

Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are commercially available in the USA.